Trial · NCT02451137
Results by group104
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 104
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia | Toujeo | 31.3 | percentage of participants | ||
Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia | Standard of Care | 27.9 | percentage of participants | ||
| Change From Baseline in HbA1c at Month 6 and Month 12 | Toujeo | Month 6 | -1.40 | Standard Error 0.030 | percentage of HbA1c |
| Change From Baseline in HbA1c at Month 6 and Month 12 | Standard of Care | Month 6 | -1.36 | Standard Error 0.030 | percentage of HbA1c |
| Change From Baseline in HbA1c at Month 6 and Month 12 | Toujeo | Month 12 | -1.29 | Standard Error 0.034 | percentage of HbA1c |
| Change From Baseline in HbA1c at Month 6 and Month 12 | Standard of Care | Month 12 | -1.24 | Standard Error 0.034 | percentage of HbA1c |
| Treatment Persistence Measured by Medication Possession Ratio (MPR) | Toujeo | Month 6 | 62.06 | Standard Deviation 26.98 | Medication Possession ratio |
| Treatment Persistence Measured by Medication Possession Ratio (MPR) | Standard of Care | Month 6 | 63.14 | Standard Deviation 28.42 | Medication Possession ratio |
| Treatment Persistence Measured by Medication Possession Ratio (MPR) | Toujeo | Month 12 | 58.21 | Standard Deviation 28.87 | Medication Possession ratio |
| Treatment Persistence Measured by Medication Possession Ratio (MPR) | Standard of Care | Month 12 | 57.82 | Standard Deviation 29.97 | Medication Possession ratio |
| Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period | Toujeo | 37.3 | percentage of participants | ||
| Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period | Standard of Care | 34.3 | percentage of participants | ||
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period | Toujeo | Month 12: <=70 mg/dL | 26.1 | percentage of participants | |
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period | Standard of Care | Month 12: <=70 mg/dL | 23.7 | percentage of participants | |
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period | Toujeo | Month 12: <54 mg/dL | 33.0 | percentage of participants | |
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period | Standard of Care | Month 12: <54 mg/dL | 29.5 | percentage of participants | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12 | Toujeo | Month 6 | -48.9 | Standard Error 1.56 | mg/dL |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12 | Standard of Care | Month 6 | -50.4 | Standard Error 1.58 | mg/dL |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12 | Toujeo | Month 12 | -48.0 | Standard Error 1.66 | mg/dL |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12 | Standard of Care | Month 12 | -47.3 | Standard Error 1.69 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02451137/results